Breast cancer cell response to genistein is conditioned by BRCA1 mutations.
Soy phytoestrogens, among which genistein, seem to protect from breast cancer development. In order to study the role of the breast tumour suppressor BRCA1 in response to genistein, we used a new breast cancer cell model: the SUM1315MO2 cell line carrying the 185delAG BRCA1 mutation, which we stably transfected with a plasmid encoding wild-type BRCA1. We showed that growth of BRCA1 mutant cells was strongly inhibited by genistein whereas it only had a weak effect in cells expressing wild-type BRCA1 protein. BRCA1 mutant cells hypersensitivity could be linked to higher expression of ERbeta gene, which suggests that genistein may be an efficient inhibitor of cancer development in BRCA1 mutant breast cancer cells.
Privat
Maud
M
Centre Jean Perrin, Département d'Oncogénétique, 58 rue Montalembert, Clermont-Ferrand Cedex 01, France.
Aubel
Corinne
C
Arnould
Stéphanie
S
Communal
Yves
Y
Ferrara
Marc
M
Bignon
Yves-Jean
YJ
D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D017209:Apoptosis; D019313:BRCA1 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control*; D002453:Cell Cycle / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects* / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D047629:Estrogen Receptor beta / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D019833:Genistein / Q000494:pharmacology*; D006801:Humans; D009154:Mutation
D016588:Anticarcinogenic Agents; D019313:BRCA1 Protein; D047629:Estrogen Receptor beta; D019833:Genistein